androsta-3,5-diene-3-ol | 442528-12-3

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 英文名称: androsta-3,5-diene-3-ol
• 英文别名: (8S,9S,10R,13S,14S)-10,13-dimethyl-2,7,8,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol
• CAS: 442528-12-3
• 化学式: C₁₉H₂₈O
• 分子量: 272.431
• InChiKey: FYRTWTNLESKYDS-VMXHOPILSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.5
• 重原子数：
  20
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.79
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Methods and compositions for treating cancer
  申请人：Cougar Biotechnology, Inc.

  公开号：EP2478907A2

  公开（公告）日：2012-07-25

  Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) androsta-5, 16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17α-hydroxylase/C17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.

  本文描述了治疗癌症的方法和组合物。更具体地说，治疗癌症的方法包括施用 17α- 羟化酶/C17,20-赖氨酸酶抑制剂，如醋酸阿比特龙（即 3β-乙酰氧基-17-(3-吡啶基) 雄甾-5,16-二烯），与至少一种额外的治疗剂如抗癌剂或类固醇结合使用。此外，还公开了包含 17α- 羟化酶/C17,20-裂解酶抑制剂和至少一种额外治疗剂（如抗癌剂或类固醇）的组合物。
• COMPOSITIONS FOR TREATING CANCER
  申请人：Janssen Oncology, Inc.

  公开号：EP3804730A1

  公开（公告）日：2021-04-14

  Methods and compositions for treating cancer are described herein. More particularly, the methods for treating cancer comprise administering a 17α-hydroxylase/C17,20-lyase inhibitor, such as abiraterone acetate (i.e., 3β-acetoxy-17-(3-pyridyl) androsta-5, 16-diene), in combination with at least one additional therapeutic agent such as an anti-cancer agent or a steroid. Furthermore, disclosed are compositions comprising a 17α-hydroxylase/C17,20-lyase inhibitor, and at least one additional therapeutic agent, such as an anti-cancer agent or a steroid.

  本文描述了治疗癌症的方法和组合物。更具体地说，治疗癌症的方法包括施用 17α- 羟化酶/C17,20-赖氨酸酶抑制剂，如醋酸阿比特龙（即 3β-乙酰氧基-17-(3-吡啶基) 雄甾-5,16-二烯），与至少一种额外的治疗剂如抗癌剂或类固醇结合使用。此外，还公开了包含 17α- 羟化酶/C17,20-裂解酶抑制剂和至少一种额外治疗剂（如抗癌剂或类固醇）的组合物。
• METHODS AND COMPOSITIONS FOR TREATING CANCER
  申请人：Cougar Biotechnology, Inc.

  公开号：EP2061561A1

  公开（公告）日：2009-05-27
• COMBINATION COMPRISING RADIUM-223 FOR THE TREATMENT OF CANCER
  申请人：Bayer Pharma Aktiengesellschaft

  公开号：EP2934545A1

  公开（公告）日：2015-10-28
• METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS
  申请人：Auerbach Alan H.

  公开号：US20090124587A1

  公开（公告）日：2009-05-14

  Methods for treating certain cancers in patients, such as mammals, using certain 17α-hydroxylase/C 17,20 -lyase inhibitors are discussed herein. More particularly, methods for treating cancers comprising administering a 17α-hydroxylase/C 17,20 -lyase inhibitor, such as abiraterone acetate (i.e. 3β-acetoxy-17-(3-pyridyl) androsta-5,16-diene) and metabolites thereof are described. In addition, methods for treating cancers that are refractory to hormone therapy or that are refractory to chemotherapy are also discussed. Finally novel dosing regimens and novel uses of the compounds discussed herein are disclosed.